查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1624377

高解析度熔體分析的全球市場規模：按產品類型、應用、最終用戶、區域分析和預測

Global High-Resolution Melting Analysis Market Size By Product Type, By Application, By End User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

高解析度熔體分析的市場規模與預測

2023年高解析度熔體分析市場規模為2.7787億美元，預計2024年至2030年複合年增長率為2.8%，到2030年將達到3.4656億美元。

高解析度熔體分析的全球市場推動因素

高解析度熔體分析市場的市場推動因素可能受到多種因素的影響。

分子生物學的發展：

隨著分子生物學技術的不斷發展，對更準確、更有效的基因分型、突變掃瞄和 DNA 甲基化分析方法的需求不斷增長。研究人員和醫生被 HRMA 卓越的敏感度和特異性所吸引。

遺傳病患病率增加：

遺傳性疾病和疾病的盛行率持續增加，需要可靠的診斷方法進行早期診斷和監測。與許多疾病相關的基因突變、突變和多態性，包括癌症、心臟病和遺傳綜合症，都可以在HRMA中找到。

向個人化醫療過渡：

隨著個人化醫療變得越來越普遍，人們越來越需要準確、快速的基因分型方法，以根據患者的基因組成來客製化治療方案。HRMA 有助於基因分型和突變分析，並有助於確定適當的治療方法和劑量。

HRMA平台技術開發：

由於 HRMA 平台的技術發展（包括軟體整合、儀器自動化和靈敏度的提高），市場正在不斷擴大。這些發展提高了結果的準確性，減少了周轉時間，並優化了工作流程效率。

研究經費和合作研究的增加：

研究經費的增加以及學術機構、研究機構和生物技術公司之間的合作正在推動 HRMA 技術的創新。因此，HRMA 的市場不斷擴大，新的應用不斷出現。

擴大臨床診斷的採用：

HRMA 高度可靠、價格實惠，並且允許同時分析多個樣本，使其越來越多地應用於臨床診斷。隨著實驗室尋求可擴展且有效的分子診斷解決方案，HRMA 已成為基因分型和突變掃瞄的理想選擇。

監管支持和標準化：

市場擴張是由監管支持和標準化計劃推動的，以確保分子診斷測試的準確性和可靠性。合規性將促進醫療保健專業人員的接受，從而提高基於 HRMA 的檢測在臨床實踐中的可接受性。

意識和教育舉措

培訓計劃和教育舉措，以及提高醫療保健專業人員對 HRMA 技術優勢的瞭解，將促進 HRMA 的廣泛使用。隨著越來越多的人瞭解 HRMA 應用程式和最佳實踐，對互聯產品和服務的需求將會增加。

限制全球高解析度熔體分析市場的因素

有幾個因素可能會成為高解析度熔體分析市場的限制和課題。這些包括：

成本高：

HRMA 所需的試劑和設備可能非常昂貴，使得該技術難以在預算有限的小型實驗室或組織中使用。

複雜：

為了準確實施和分析調查結果，HRMA 需要特殊程度的能力。由於 HRMA 的複雜性，有些人可能會猶豫是否要實施 HRMA。

與替代技術的競爭：

新一代定序、數位PCR、即時PCR和其他分子生物學技術具有可比較的能力，並且可能與HRMA在市場上競爭。

使用限制：

儘管 HRMA 對於 SNP 基因分型、突變掃瞄和其他應用很有用，但在某些研究和診斷情況下，其用途可能不如其他方法。

結果解讀：

一些使用者可能會發現 HRMA 結果難以理解，尤其是在處理複雜樣本或低品質 DNA 時。

標準化和驗證：

由於難以確保多個實驗室獲得一致且可靠的結果，因此需要標準化和驗證工作，這可能會阻礙在某些情況下的採用。

監管障礙：

遵守與臨床診斷應用相關的法規可能很困難，並且限制了某些地區或某些應用的市場擴張。

樣品品質和數量：

HRMA 性能可能會受到 DNA 樣本品質和數量的影響，這可能成為某些測試和診斷情況的限制。

有限的教育和意識：

HRMA 廣泛使用的障礙之一可能是研究人員和醫生不瞭解工具的好處和潛力。

基礎設施需求：

HRMA 所需的實驗室設備是獨特的，例如螢光檢測系統和熱循環儀，並且並不總是可用。

目錄

第1章 全球高解析度熔化分析市場簡介

  • 市場概況
  • 調查範圍
  • 先決條件

第 2 章執行摘要

第3章 驗證市場研究研究方法

  • 數據挖掘
  • 驗證
  • 一次資料
  • 數據源列表

第4章高分辨率熔體分析的全球市場展望

  • 概述
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力模型
  • 價值鏈分析
  • 監管框架

第5章高解析度熔體分析的全球市場：按類型

  • 機器
  • 試劑/耗材

第6章 高解析度熔體分析的全球市場：依應用分類

  • 基因分型
  • 突變掃瞄
  • 物種鑑定
  • 病原鑑定
  • 表觀遺傳學

第7章 高解析度熔體分析的全球市場：依最終使用者劃分

  • 檢驗實驗室
  • 醫院和診斷中心
  • 製藥和生物技術公司
  • 合約開發組織（CRO）

第8章高解析度熔體分析的全球市場：按地區劃分

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太其他地區
  • 世界其他地區
    • 拉丁美洲
    • 中東/非洲

第9章 全球高解析度熔化分析市場競爭態勢

  • 概述
  • 企業市佔率
  • 供應商情況
  • 主要發展策略

第10章 公司簡介

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffman-La Roche Ltd.
  • Qiagen N.V.
  • Illumina Inc.
  • Agilent Technologies Inc.
  • Biomerieux SA
  • Meridian Bioscience Inc.
  • Novacyt Group
  • Premier Biosoft
  • Azura Genomics
  • Canon Biomedical Inc.

第11章附錄

  • 相關報導
簡介目錄
Product Code: 24077

High-Resolution Melting Analysis Market Size And Forecast

High-Resolution Melting Analysis Market size was valued at USD 277.87 Million in the year 2023 and is projected to reach USD 346.56 Million by 2030 , growing at a CAGR of 2.8% from 2024 to 2030.

Global High-Resolution Melting Analysis Market Drivers

The market drivers for the High-Resolution Melting Analysis Market can be influenced by various factors. These may include:

Developments in Molecular Biology:

With the constant evolution of molecular biology techniques, there is an increasing demand for more precise and effective genotyping, mutation scanning, and DNA methylation analysis approaches. Researchers and physicians are drawn to HRMA because of its excellent sensitivity and specificity.

Growing Prevalence of Genetic Disorders:

Robust diagnostic methods are necessary for early diagnosis and monitoring of genetic disorders and diseases, as their prevalence continues to rise. Genetic variants, mutations, and polymorphisms linked to a number of illnesses, such as cancer, heart conditions, and genetic syndromes, can be found with HRMA.

Transition to Personalized Medicine:

As personalized medicine gains popularity, there is an increased need for accurate and quick genotyping methods to customize treatment regimens based on a patient's genetic composition. HRMA makes genotyping and mutation analysis easier, which helps determine the right treatments and dosages.

Technological Development in HRMA Platforms:

The market is expanding as a result of ongoing technological developments in HRMA platforms, such as software integration, instrument automation, and increased sensitivity. These developments increase the accuracy of the results, speed up turnaround times, and optimize workflow efficiency.

Growing Research Funding and Collaborations:

Innovation in HRMA technology is being driven by an increase in research funding as well as collaborations between academic institutions, research organizations, and biotechnology firms. As a result, the market for HRMA grows and new applications are created.

Growing Adoption in Clinical Diagnostics:

Because of HRMA's dependability, affordability, and capacity for simultaneous analysis of several samples, its use in clinical diagnostics is growing. As labs look for scalable and effective molecular diagnostics solutions, HRMA becomes the go-to option for genotyping and mutation scanning.

Regulatory Support and Standardization:

Market expansion is facilitated by regulatory support and standardization programmes that work to guarantee the accuracy and dependability of molecular diagnostic tests. Adoption among healthcare practitioners is fueled by regulatory compliance, which improves the acceptability of HRMA-based assays in clinical settings.

Raising Awareness and Education Initiatives:

Training programmes and educational initiatives, in conjunction with growing healthcare professional knowledge of the advantages of HRMA technology, encourage its broad use. The need for connected goods and services rises as more people become aware of HRMA applications and best practices.

Global High-Resolution Melting Analysis Market Restraints

Several factors can act as restraints or challenges for the High-Resolution Melting Analysis Market. These may include:

High Cost:

Because the reagents and equipment needed for HRMA can be pricey, smaller labs or organizations with tighter budgets may find it difficult to use the technique.

Complexity:

To conduct and analyze findings accurately, HRMA calls for a particular level of competence. Some people may be discouraged from embracing the technology due to its intricacy.

Competition from Alternative Technologies:

Next-generation sequencing, digital PCR, real-time PCR, and other molecular biology techniques have comparable capabilities and could face off against HRMA in the market.

Restricted Uses:

Although HRMA is helpful for SNP genotyping, mutation scanning, and other uses, in some research or diagnostic situations, its usefulness may be less than that of other methods.

Interpretation of Results:

Some users may find it difficult to understand HRMA results, particularly when working with complex samples or low-quality DNA.

Standardization and Validation:

It might be difficult to ensure consistent and trustworthy results across several laboratories, necessitating efforts at standardization and validation that might discourage adoption in particular contexts.

Regulatory Obstacles:

Complying with regulations, such as those pertaining to clinical diagnostic applications, can be difficult and may restrict market expansion in particular areas or for particular uses.

Sample Quality and Quantity:

HRMA performance may be impacted by DNA sample quality and quantity, which may be a constraint in some study or diagnostic contexts.

Limited Education and Awareness:

One obstacle to the broad use of HRMA may be researchers' and doctors' ignorance of the tools' advantages and potential.

Infrastructure Requirements:

The laboratory equipment needed for HRMA is unique, including things like fluorescent detection systems and thermocyclers, which might not always be accessible.

Global High-Resolution Melting Analysis Market Segmentation Analysis

The Global High-Resolution Melting Analysis Market is Segmented on the basis of Product Type, Application, End User And Geography.

High-Resolution Melting Analysis Market, By Product Type

  • Instruments:
  • High-resolution melting (HRM) instruments used for analysis.
  • Reagents and Consumables:
  • Chemicals and consumables required for high-resolution melting analysis.

High-Resolution Melting Analysis Market, By Application

  • Genotyping:
  • Analysis of genetic variations within a population.
  • Mutation Scanning:
  • Detection of mutations in DNA sequences.
  • Species Identification:
  • Identifying different species based on genetic markers.
  • Pathogen Identification:
  • Detecting pathogens such as bacteria or viruses in samples.
  • Epigenetics:
  • Studying modifications to DNA that do not involve changes in the underlying DNA sequence.

High-Resolution Melting Analysis Market, By End-User

  • Research Laboratories:
  • Academic and industrial research facilities.
  • Hospitals and Diagnostic Centers:
  • Clinical settings for disease diagnosis and genetic testing.
  • Pharmaceutical and Biotechnology Companies:
  • Drug discovery and development.
  • Contract Research Organizations (CROs):
  • Outsourced research services.

High-Resolution Melting Analysis Market, By Geography

  • North America:
  • Includes the U.S., Canada, and Mexico.
  • Europe:
  • Encompasses countries within the European Union and other European nations.
  • Asia-Pacific:
  • Covers countries in East Asia, South Asia, Southeast Asia, and Oceania.
  • Latin America:
  • Includes Central and South American countries.
  • Middle East and Africa (MEA):
  • Encompasses countries in the Middle East and the African continent.

Key Players

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffman-La Roche Ltd.
  • Qiagen N.V.
  • Illumina Inc.
  • Agilent Technologies Inc.
  • Biomerieux SA
  • Meridian Bioscience Inc.
  • Novacyt Group
  • Premier Biosoft
  • Azura Genomics
  • Canon Biomedical Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET, BY TYPE

  • 5.1 Instruments
  • 5.2 Reagents and Consumables

6 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET, BY APPLICATION

  • 6.1 Genotyping
  • 6.2 Mutation Scanning
  • 6.3 Species Identification
  • 6.4 Pathogen Identification
  • 6.5 Epigenetics

7 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET, BY END-USER

  • 7.1 Research Laboratories
  • 7.2 Hospitals and Diagnostic Centers
  • 7.3 Pharmaceutical and Biotechnology Companies
  • 7.4 Contract Research Organizations (CROs)

8 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL HIGH-RESOLUTION MELTING ANALYSIS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Share
  • 9.3 Vendor Landscape
  • 9.4 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Bio-Rad Laboratories Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 F. Hoffman-La Roche Ltd.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Qiagen N.V.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Illumina Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Agilent Technologies Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Biomerieux SA
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Meridian Bioscience Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Novacyt Group
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Premier Biosoft
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Azura Genomics
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Canon Biomedical Inc.
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments

11 Appendix

  • 11.1 Related Reports